Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) ...

RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

It’s what’s being called a “Quad-demic,” with cases on the rise for COVID-19, Respiratory syncytial virus (RSV), Influenza, ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

It is also possible for people to get infected from contact with a sick cat, Troisi said. The situation with the virus is ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

With a recent surge in influenza, COVID-19, norovirus, respiratory syncytial virus (RSV), and other respiratory viruses, it's ...

As of Jan. 20, the CDC reports that RSV activity has peaked in most of the U.S., particularly among young children—a group ...

Host immune and proinflammatory responses to respiratory virus infections play key roles ... indicating a central role of viral replication in driving these responses. [45] Mixed infections ...